Systemic therapy of atopic dermatitis: Welcome to the revolution

Document Type

Conference Proceeding

Publication Date

2017

Publication Title

Semin Cutan Med Surg

Abstract

Until recently, systemic therapy of atopic dermatitis was limited to off-label use of immunomodulators, which can pose significant safety concerns, and treatment with systemic corticosteroids, not recommended in the most recent guidelines. The introduction of dupilumab in 2017 marked a major advance in systemic therapy for atopic dermatitis. It has demonstrated long-term efficacy in adults with moderate to severe disease, and is being studied in children. Several other biologic agents and "small molecules" with varying mechanisms of action are in phase 2 or 3 development. (C) 2017 published by Frontline Medical Communications

Volume

36

Issue

Suppl 4

First Page

S103

Last Page

S105

This document is currently not available here.

Share

COinS